W. Neil Palmer
In its December 2019 NEWSletter[1], the Patented Medicine Prices Review Board (PMPRB) is “reminding” patentees that they are required under the Patent Act (the Act) and the Patented Medicines Regulations (the Regulations) to file all zero-dollar sales, referring specifically to free goods. This “reminder” is troubling ... Read More
News & Events
14
Jan2020
13
Jan2020
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review process updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information, please consult the CADTH website.
CADTH released new updates to economic Category 1 Requirements ... Read More
06
Jan2020
Recently, the deadline for providing written submissions on the PMPRB’s proposed new Guidelines was extended until January 31, 2020. As part of the ongoing consultation process, the PMPRB has reserved three days in January for bilateral meetings with individual patentees: January 8, 9, and 10, 2020. Meetings will be scheduled on ... Read More
18
Dec2019
10
Dec2019
Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.
... Read More
27
Nov2019
CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review processes updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information on this review, please consult the CADTH website.
This CADTH update primarily ... Read More
26
Nov2019
REGISTRATION IS OPEN!
Learn how the new PMPRB amendments and guidelines will affect your pharmaceutical pricing, negotiations and reimbursement
Join PDCI Market Access Inc., Canada’s leading pricing and reimbursement consultancy, for industry-only sessions on the pricing guidelines, led by senior members ... Read More
22
Nov2019
Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.
Summary of New pCPA Activity Since ... Read More
21
Nov2019
WHITEPAPER: Debunking Price Regulations Based on the Pharmacoeconomic Value Factor
/ Health Canada, News, PDCI, PMPRB, Publications
Pricing changes for Canada’s patented medicines are on their way and stakeholders are anticipating the release of the updated guidelines. How will the guidelines be operationalized? How will the new pharmacoeconomic factors be implemented? In an effort to answer these questions, PDCI has attempted to reverse-engineer the proposed Pharmacoeconomic Value ... Read More
01
Nov2019
Mark your calendar: On Wednesday, November 6th at 11:00 a.m., the Canadian Real-World Evidence for Value of Cancer Drugs (CanReValue) team will host a webinar to present the development and testing of a framework that will be used to generate and apply real-world evidence (RWE) in funding decisions for ... Read More